Seeing Is Believing
Currently out of the existing stock ratings of Kyle Rose, 170 are a BUY (85.86%), 28 are a HOLD (14.14%).
Analyst Kyle Rose, currently employed at CANACCORD, carries an average stock price target met ratio of 53.94% that have a potential upside of 27.53% achieved within 194 days.
Kyle Rose’s has documented 417 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on AXGN, Axogen at 24-Feb-2025.
Analyst best performing recommendations are on XENT (INTERSECT ENT).
The best stock recommendation documented was for XENT (INTERSECT ENT) at 1/11/2021. The price target of $25 was fulfilled within 2 days with a profit of $2.78 (12.51%) receiving and performance score of 62.56.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$22
$8.04 (57.59%)
$21
2 months 6 days ago
(03-Aug-2025)
0/3 (0%)
$7.13 (47.95%)
Buy
$16
$2.04 (14.61%)
$16
5 months 8 days ago
(01-May-2025)
11/21 (52.38%)
$4 (33.33%)
227
Buy
$15
$1.04 (7.45%)
$13
5 months 8 days ago
(01-May-2025)
12/18 (66.67%)
$3 (25.00%)
188
Buy
$20
$6.04 (43.27%)
$20
5 months 26 days ago
(13-Apr-2025)
1/10 (10%)
$9.82 (96.46%)
51
Buy
$15
$1.04 (7.45%)
$16
11 months 9 days ago
(30-Oct-2024)
5/8 (62.5%)
$7.15 (91.08%)
210
What Year was the first public recommendation made by Kyle Rose?